SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indian pharma export to US likely to rise in 2017-18: Care Ratings

18 Jul 2017 Evaluate

On the back of expectations that $55 billion worth of drugs will become off-patented during 2017-19, credit rating agency, Care ratings in its latest report has said that Indian pharma export volumes to US are likely to rise in 2017-18 and will create an opportunity for Contract Research and Manufacturing Services (CRAMS) segment.

Of the total exports of $ 16.8 billion during the year 2016-17, majority of the exports, accounting for 40.6% were to the American continent followed by 19.7% to Europe, 19.1% to Africa and 18.8% within Asia. The credit rating agency however reported that due to pricing pressure and stiff competition, the total pharma exports from India during April-May 2017 fell by 8.5 percent to $2.5 billion and exports to USA decreased by 23% y-o-y to $723.4 million during the same period, adding that the industry will continue to witness pricing pressure in the US generics market due to consolidation of distribution channels and increase in competition.

The report further said that the pharma industry is also likely to face competition from other countries to get Abbreviated New Drug Application (ANDA) approval. It noted that in domestic market, the revenue growth rate of the industry was impacted on the back of stricter enforcement of Drug Price Control Order and going forward, with implementation of GST, there will be no major change in the prices of medicines.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: